Ciprofloxacin | CAS#85721-33-1 | antibiotic

MedKoo Cat#: 461156 | Name: Ciprofloxacin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ciprofloxacin is a widely used antibiotic.

Chemical Structure

Ciprofloxacin

CAS#85721-33-1 (free base)

Theoretical Analysis

MedKoo Cat#: 461156

Name: Ciprofloxacin

CAS#: 85721-33-1 (free base)

Chemical Formula: C17H18FN3O3

Exact Mass: 331.1332

Molecular Weight: 331.34

Elemental Analysis: C, 61.62; H, 5.48; F, 5.73; N, 12.68; O, 14.49

Price and Availability

Size	Price	Availability
1g	USD 90.00	Ready to ship
2g	USD 150.00	Ready to ship
5g	USD 250.00	Ready to ship
10g	USD 400.00	Ready to ship
25g	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

85721-33-1 (free base) 86393-32-0 (HCl hydrate) 86483-48-9 (xHCl) 93107-08-5 (HCl) 96186-80-0 (lactate) 97867-33-9 (lactate)

Synonym

Ciprofloxacin; Baflox; Cetraxal; Ciprolin; Fimoflox; Proflaxin; Spitacin;

IUPAC/Chemical Name

1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

InChi Key

MYSWGUAQZAJSOK-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

SMILES Code

OC(C1=CN(c2c(C1=O)cc(F)c(N3CCNCC3)c2)C4CC4)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Certificate of Analysis

View CoA: current batch, Lot#C24B05B01

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Quinolone

In vitro activity:

Ciprofloxacin is a broad spectrum antibacterial drug to which most Gram-negative bacteria are highly susceptible in vitro and many Gram-positive bacteria are susceptible or moderately susceptible. Reference: Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003. PMID: 3292209.

In vivo activity:

Ciprofloxacin has been extensively investigated in various animal models of infection. These studies have demonstrated ciprofloxacin to possess in-vivo activity comparable to its activity previously demonstrated in vitro. Reference: Peterson LR. Animal models: the in-vivo evaluation of ciprofloxacin. J Antimicrob Chemother. 1986 Nov;18 Suppl D:55-64. doi: 10.1093/jac/18.supplement_d.55. PMID: 3542949.

	Solvent	mg/mL	mM
Solubility
	0.1M HCl	16.7	50.31
	H2O	6.8	20.46
	DMSO	4.9	14.67

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 331.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

In vitro protocol:

1: Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003. PMID: 3292209. 2: Sanders CC. Ciprofloxacin: in vitro activity, mechanism of action, and resistance. Rev Infect Dis. 1988 May-Jun;10(3):516-27. doi: 10.1093/clinids/10.3.516. PMID: 3293157.

In vivo protocol:

1: Peterson LR. Animal models: the in-vivo evaluation of ciprofloxacin. J Antimicrob Chemother. 1986 Nov;18 Suppl D:55-64. doi: 10.1093/jac/18.supplement_d.55. PMID: 3542949. 2: Egorov AR, Kurliuk AV, Rubanik VV, Kirichuk AA, Khubiev O, Golubev R, Lobanov NN, Tskhovrebov AG, Kritchenkov AS. Chitosan-Based Ciprofloxacin Extended Release Systems: Combined Synthetic and Pharmacological (In Vitro and In Vivo) Studies. Molecules. 2022 Dec 13;27(24):8865. doi: 10.3390/molecules27248865. PMID: 36557998; PMCID: PMC9784460.

1: Okoye NV, Oyawole MR, Uzochukwu PU, Oyetunde OO. Review of ciprofloxacin use in children. Nig Q J Hosp Med. 2013 Jan-Mar;23(1):43-7. Review. PubMed PMID: 24579494. 2: Kaplan YC, Koren G. Use of ciprofloxacin during breastfeeding. Can Fam Physician. 2015 Apr;61(4):343-4. Review. PubMed PMID: 26052598; PubMed Central PMCID: PMC4396759. 3: Justo JA, Danziger LH, Gotfried MH. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2013 Oct;7(5):272-87. doi: 10.1177/1753465813487412. Epub 2013 May 20. Review. PubMed PMID: 23690368. 4: Samarei R. Comparison of local and systemic ciprofloxacin ototoxicity in the treatment of chronic media otitis. Glob J Health Sci. 2014 Sep 18;6(7 Spec No):144-9. doi: 10.5539/gjhs.v6n7p144. PubMed PMID: 25363170; PubMed Central PMCID: PMC4796472. 5: Du J, El-Sherbiny IM, Smyth HD. Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery. AAPS PharmSciTech. 2014 Dec;15(6):1535-44. doi: 10.1208/s12249-014-0176-x. Epub 2014 Jul 31. PubMed PMID: 25079240; PubMed Central PMCID: PMC4245439. 6: Fahmy S, Abu-Gharbieh E. In vitro dissolution and in vivo bioavailability of six brands of ciprofloxacin tablets administered in rabbits and their pharmacokinetic modeling. Biomed Res Int. 2014;2014:590848. doi: 10.1155/2014/590848. Epub 2014 Jun 3. PubMed PMID: 24995312; PubMed Central PMCID: PMC4065682. 7: Stass H, Delesen H, Nagelschmitz J, Staab D. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J Aerosol Med Pulm Drug Deliv. 2015 Apr;28(2):106-15. doi: 10.1089/jamp.2013.1056. Epub 2014 Jul 22. PubMed PMID: 25050456. 8: Marquez B, Pourcelle V, Vallet CM, Mingeot-Leclercq MP, Tulkens PM, Marchand-Bruynaert J, Van Bambeke F. Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity. Pharm Res. 2014 May;31(5):1290-301. doi: 10.1007/s11095-013-1250-x. Epub 2013 Dec 5. PubMed PMID: 24306327. 9: Barbosa L, Johnson SP, Papich MG, Gulland F. PHARMACOKINETICS OF SINGLE-DOSE ORALLY ADMINISTERED CIPROFLOXACIN IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). J Zoo Wildl Med. 2015 Jun;46(2):266-72. doi: 10.1638/2014-0159R.1. PubMed PMID: 26056878. 10: Haeseker M, Stolk L, Nieman F, Hoebe C, Neef C, Bruggeman C, Verbon A. The ciprofloxacin target AUC : MIC ratio is not reached in hospitalized patients with the recommended dosing regimens. Br J Clin Pharmacol. 2013 Jan;75(1):180-5. doi: 10.1111/j.1365-2125.2012.04337.x. PubMed PMID: 22616681; PubMed Central PMCID: PMC3555057. 11: Matsuo K, Fujiwara K, Omuro N, Kimura I, Kobayashi K, Yoshio T, Takahara A. Effects of the fluoroquinolone antibacterial drug ciprofloxacin on ventricular repolarization in the halothane-anesthetized Guinea pig. J Pharmacol Sci. 2013;122(3):205-12. Epub 2013 Jun 27. PubMed PMID: 23803533. 12: Castro W, Navarro M, Biot C. Medicinal potential of ciprofloxacin and its derivatives. Future Med Chem. 2013 Jan;5(1):81-96. doi: 10.4155/fmc.12.181. Review. PubMed PMID: 23256815. 13: Ong HX, Traini D, Cipolla D, Gonda I, Bebawy M, Agus H, Young PM. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res. 2012 Dec;29(12):3335-46. doi: 10.1007/s11095-012-0827-0. Epub 2012 Jul 26. PubMed PMID: 22833052. 14: Sirivisoot S, Harrison BS. Magnetically stimulated ciprofloxacin release from polymeric microspheres entrapping iron oxide nanoparticles. Int J Nanomedicine. 2015 Jul 9;10:4447-58. doi: 10.2147/IJN.S82830. eCollection 2015. PubMed PMID: 26185446; PubMed Central PMCID: PMC4501354. 15: Chiesa OA, Idowu OR, Heller D, Smith M, Nochetto C, Chamberlain PL, Gehring R, von Bredow J. A Holstein cow-calf model for the transfer of ciprofloxacin through milk after a long-term intravenous infusion. J Vet Pharmacol Ther. 2013 Oct;36(5):425-33. doi: 10.1111/jvp.12014. Epub 2012 Oct 3. PubMed PMID: 23030707. 16: Ross AG, Benton BM, Chin D, De Pascale G, Fuller J, Leeds JA, Reck F, Richie DL, Vo J, LaMarche MJ. Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3468-75. doi: 10.1016/j.bmcl.2015.07.010. Epub 2015 Jul 9. PubMed PMID: 26189081. 17: Waxman S, Prados AP, de Lucas JJ, San Andrés MI, Regner P, de Oliveira VC, de Roodt A, Rodríguez C. Pharmacokinetic behavior of enrofloxacin and its metabolite ciprofloxacin in urutu pit vipers (Bothrops alternatus) after intramuscular administration. J Zoo Wildl Med. 2014 Mar;45(1):78-85. PubMed PMID: 24712165. 18: Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Biopharm Drug Dispos. 2011 Apr;32(3):168-74. doi: 10.1002/bdd.748. Epub 2011 Mar 1. PubMed PMID: 21360715. 19: Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J. 2011 Feb;30(2):e29-37. doi: 10.1097/INF.0b013e3181fe353d. Review. PubMed PMID: 21048525. 20: Suresh N, Nagesh HN, Sekhar KV, Kumar A, Shirazi AN, Parang K. Synthesis of novel ciprofloxacin analogues and evaluation of their anti-proliferative effect on human cancer cell lines. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6292-5. doi: 10.1016/j.bmcl.2013.09.077. Epub 2013 Oct 1. PubMed PMID: 24138941.